康哲药业就用于破伤风被动免疫和狂犬病被动免疫的两款创新生物制剂达成合作
Sep 23, 2025 11:16 HKT |  |
|
康哲藥業就用於破傷風被動免疫和狂犬病被動免疫的兩款創新生物製劑達成合作
Sep 23, 2025 11:16 HKT | |
|
EASD 2025 | 君圣泰医药口头报告HTD1801治疗2型糖尿病临床3期研究成果
Sep 17, 2025 08:00 HKT |  |
|
EASD 2025 | 君聖泰醫藥口頭報告HTD1801治療2型糖尿病臨床3期研究成果
Sep 17, 2025 08:00 HKT | |
|
HKTDC releases research report on biomedicine, Industry development drives GBA global tech leadership
Sep 15, 2025 15:19 HKT |  |
|
Resilient Interim Results, Essex Bio-Technology Drives Growth and Innovation
Aug 26, 2025 20:00 HKT |  |
|
Innovative Vaccine Engine Continues to Drive Growth: CanSinoBIO Enters a New Growth Cycle
Aug 20, 2025 20:30 HKT |  |
|
創新疫苗引擎持續驅動 康希諾開啟新增長週期
Aug 20, 2025 20:22 HKT | |
|
创新疫苗引擎持续驱动 康希诺开启新增长周期
Aug 20, 2025 20:02 HKT | |
|
CMS (867.HK, 8A8.SG) Reports Growth in Revenue and Profit for H1 2025, Strategic Transformation Unlocks New Drivers
Aug 19, 2025 15:00 HKT | |
|
康哲药业（867.HK，8A8.SG）上半年营收净利双升 战略转型跑出增长新动能
Aug 19, 2025 11:53 HKT | |
|
康哲藥業（867.HK，8A8.SG）上半年營收淨利雙升 戰略轉型跑出增長新動能
Aug 19, 2025 11:53 HKT | |
|
NMPA已受理亿胜生物关于EB12-20145P（HLX04-O）用于治疗湿性年龄相关性黄斑变性的生物制品许可申请
Aug 13, 2025 21:25 HKT | |
|
NMPA Accepted Essex's Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration
Aug 13, 2025 20:24 HKT | |
|
NMPA已受理億勝生物關於EB12-20145P（HLX04-O）用於治療濕性年齡相關性黃斑變性的生物製品許可申請
Aug 13, 2025 20:24 HKT | |
|
China Medical System (867.HK, 8A8.SG) NDA for the Improved New Drug ZUNVEYL for Alzheimer's Disease Accepted in China
Jul 29, 2025 04:00 HKT | |
|
亿胜生物多剂量地夸磷索钠滴眼液获中国国家药品监督管理局批准上市
Jul 25, 2025 10:52 HKT | |
|
億勝生物多劑量地誇磷索鈉滴眼液獲中國國家藥品監督管理局批准上市
Jul 25, 2025 10:52 HKT | |
|
Multi-Dose Diquafosol Sodium Eye Drops Obtained Approval from NMPA for Commercialisation in China
Jul 25, 2025 10:52 HKT | |
|
冠科生物圣地亚哥实验室获 CLIA 认证 增强临床试验支持能力
Jul 23, 2025 09:00 HKT |  |
|